A Phase 1, Single-Center, Open-Label, Randomized, Single-Dose, 2-Period, Crossover Study to Evaluate the Potential Impact of High-fat Meal on the Pharmacokinetics of CRS3123 200 mg Capsule in Healthy Adult Participants
Latest Information Update: 29 May 2025
At a glance
- Drugs CRS 3123 (Primary)
- Indications Clostridium difficile infections
- Focus Pharmacokinetics
- Sponsors Crestone
Most Recent Events
- 29 May 2025 New trial record